Comorbidities in chronic neuropathic pain
Another randomized controlled trial by Zhang et al., 2025 was assessed as low risk of bias, with adequate randomization, outcome completeness, and statistical analysis
It is the first new molecular entity approved under the program, not the first drug.
* All comparisons are on a year over year basis and compare the first quarter of fiscal 2025 to the first quarter of fiscal 2024, unless otherwise noted
Although this enzyme is very important in this process, other enzymes such as CYP3A4/5 are also involved (see the diagram)
Centrifuge at 8000 g for 10 minutes at 4, take the supernatant and place it at 4 for test